{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:17:42Z","timestamp":1791494262042,"version":"4.3.4"},"reference-count":71,"publisher":"Bentham Science Publishers Ltd.","issue":"46","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,4,26]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>The use of single RAS-blockade is currently the recommended first-line treatment for\nproteinuric diabetic or non-diabetic nephropathy, as these agents were repeatedly shown in studies with hard renal\noutcomes to retard the progression of renal injury. However, CKD will continue to progress on optimum single\nRAS-blockade, and other options to ameliorate renal injury were explored. Dual RAS-blockade was associated\nwith an increased risk of adverse-events with no apparent benefits and, therefore, is currently abandoned.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Based on the phenomenon of aldosterone escape and the well-documented harmful effects of aldosterone on renal\ntissue, several randomized trials have studied the effects of a MRA in diabetic and non-diabetic nephropathy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method:<\/jats:title>\n<jats:p> This is a review of the literature in relevance to data evaluating the effect of MRA on renal outcomes.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Studies with spironolactone and eplerenone added to single RAS-blockade showed that these agents are\nassociated with greater reductions in urine albumin or protein excretion compared to either placebo or dual RASblockade.\nHowever, studies with these agents on hard renal outcomes are currently missing and the reasonable\nskepticism of physicians on the real-world incidence of hyperkalemia in CKD patients are limiting their use. A\nnon-steroidal MRA, finerenone, has also great potency in decreasing albuminuria in diabetic nephropathy with\npossibly lower rates of hyperkalemia. Two multi-center clinical trials examining the effect of finerenone on hard\ncardiovascular and renal outcomes are currently ongoing.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>MRAs are able to reduce albuminuria and proteinuria on top of single RAS-blockade in patients\nwith proteinuric CKD. Ongoing clinical trials are expected to clarify whether such an effect is accompanied by\ndelay in CKD progression.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1381612825666190306162658","type":"journal-article","created":{"date-parts":[[2019,3,8]],"date-time":"2019-03-08T06:33:12Z","timestamp":1552026792000},"page":"5528-5536","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Mineralocorticoid Receptor Antagonists for Nephroprotection: Current Evidence and Future Perspectives"],"prefix":"10.2174","volume":"24","author":[{"given":"Pantelis A.","family":"Sarafidis","sequence":"first","affiliation":[{"name":"Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Memmos","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Eleni","family":"Alexandrou","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Papagianni","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1093\/ndt\/gfl309","volume":"21","author":"Sarafidis P.A.","year":"2006","unstructured":"Sarafidis PA, Bakris GL. Nephrol Dial Transplant, Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease., 2006, 21, 2366-2374,","journal-title":"Nephrol Dial Transplant"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(12)60572-8","volume":"380","author":"Tonelli M.","year":"2012","unstructured":"Tonelli M, Muntner P, Lloyd A. Lancet, Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study., 2012, 380, 807-814,","journal-title":"Lancet"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/ki.2010.522","volume":"79","author":"Couser W.G.","year":"2011","unstructured":"Couser WG, Riella MC. Kidney Int, World Kidney Day 2011: protect your kidneys, save your heart., 2011, 79, 483-485,","journal-title":"Kidney Int"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/j.ajkd.2006.10.014","volume":"49","author":"Sarafidis P.A.","year":"2007","unstructured":"Sarafidis PA, Khosla N, Bakris GL. Am J Kidney Dis, Antihypertensive therapy in the presence of proteinuria., 2007, 49, 12-26,","journal-title":"Am J Kidney Dis"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"c147","DOI":"10.1159\/000337571","volume":"120","author":"Sarafidis P.A.","year":"2012","unstructured":"Sarafidis PA, Sharpe CC, Wood E. Nephron Clin Pract, Prevalence, patterns of treatment, and control of hypertension in predialysis patients with chronic kidney disease., 2012, 120, c147-c155,","journal-title":"Nephron Clin Pract"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"Go A.S.","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. N Engl J Med, Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization., 2004, 351, 1296-1305,","journal-title":"N Engl J Med"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cll.2006.06.005","volume":"26","author":"Khosla N.","year":"2006","unstructured":"Khosla N, Sarafidis PA, Bakris GL. Clin Lab Med, Microalbuminuria., 2006, 26, 635-653,","journal-title":"Clin Lab Med"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"","year":"2013","unstructured":". Kidney Int, Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease., 2013, 3, 1-150,","journal-title":"Kidney Int"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.0197-3118.2006.05470.x","volume":"1","author":"Sarafidis P.A.","year":"2006","unstructured":"Sarafidis PA, Whaley-Connell A, Sowers JR, Bakris GL. J Cardiometab Syndr, Cardiometabolic syndrome and chronic kidney disease: what is the link?, 2006, 1, 58-65,","journal-title":"J Cardiometab Syndr"},{"key":"ref=10","first-page":"693","volume":"98","author":"Sarafidis P.A.","year":"2007","unstructured":"Sarafidis PA. Minerva Med, Proteinuria: natural course, prognostic implications and therapeutic considerations., 2007, 98, 693-711,","journal-title":"Minerva Med"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/ki.2013.355","volume":"85","author":"Sarafidis P.A.","year":"2014","unstructured":"Sarafidis PA, Ruilope LM. Kidney Int, Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?, 2014, 85, 536-546,","journal-title":"Kidney Int"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1470320312439140","volume":"13","author":"Sarafidis P.A.","year":"2012","unstructured":"Sarafidis PA, Ruilope LM. J Renin Angiotensin Aldosterone Syst, Cardiorenal disease development under chronic renin-angiotensin-aldosterone system suppression., 2012, 13, 217-219,","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/HJH.0b013e32834e997f","volume":"30","author":"Sarafidis P.A.","year":"2012","unstructured":"Sarafidis PA, Bakris G. J Hypertens, A reappraisal of renin-angiotensin system blockade on microalbuminuria development: do they offer anything unique?, 2012, 30, 48-50,","journal-title":"J Hypertens"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","volume":"3","author":"Bomback A.S.","year":"2007","unstructured":"Bomback AS, Klemmer PJ. Nat Clin Pract Nephrol, The incidence and implications of aldosterone breakthrough., 2007, 3, 486-492,","journal-title":"Nat Clin Pract Nephrol"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x","volume":"66","author":"Hollenberg N.K.","year":"2004","unstructured":"Hollenberg NK. Kidney Int, Aldosterone in the development and progression of renal injury., 2004, 66, 1-9,","journal-title":"Kidney Int"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00004872-200103000-00001","volume":"19","author":"Lim P.O.","year":"2001","unstructured":"Lim PO, Young WF, MacDonald TM. J Hypertens, A review of the medical treatment of primary aldosteronism., 2001, 19, 353-361,","journal-title":"J Hypertens"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski P.","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD. Eur J Heart Fail, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC., 2016, 18, 891-975,","journal-title":"Eur J Heart Fail"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"Pitt B.","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ. N Engl J Med, The effect of spironolactone on morbidity and mortality in patients with severe heart failure., 1999, 341, 709-717,","journal-title":"N Engl J Med"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.2174\/1381612823666170206154706","volume":"23","author":"Faselis C.","year":"2017","unstructured":"Faselis C, Boutari C, Doumas M, Imprialos K, Stavropoulos K, Kokkinos P. Curr Pharm Des, Novel drugs for hypertension and heart failure: struggling for a place under the sun., 2017, 23, 1540-1550,","journal-title":"Curr Pharm Des"},{"key":"ref=20","first-page":"S14","volume":"26","author":"Jeunemaitre X.","year":"1988","unstructured":"Jeunemaitre X, Kreft-Jais C, Chatellier G. Kidney Int Suppl, Long-term experience of spironolactone in essential hypertension., 1988, 26, S14-S17,","journal-title":"Kidney Int Suppl"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s11906-004-0051-3","volume":"6","author":"Weinberger M.H.","year":"2004","unstructured":"Weinberger MH. Curr Hypertens Rep, The use of selective aldosterone antagonists., 2004, 6, 342-345,","journal-title":"Curr Hypertens Rep"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1097\/MEG.0000000000000548","volume":"28","author":"Pericleous M.","year":"2016","unstructured":"Pericleous M, Sarnowski A, Moore A, Fijten R, Zaman M. Eur J Gastroenterol Hepatol, The clinical management of abdominal ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: a review of current guidelines and recommendations., 2016, 28, e10-e18,","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"Williams B.","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S. Lancet, Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial., 2015, 386, 2059-2068,","journal-title":"Lancet"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"Bakris G.L.","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC. JAMA, Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial., 2015, 314, 884-894,","journal-title":"JAMA"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"Lewis E.J.","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. N Engl J Med, The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy., 1993, 329, 1456-1462,","journal-title":"N Engl J Med"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"Brenner B.M.","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D. N Engl J Med, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy., 2001, 345, 861-869,","journal-title":"N Engl J Med"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"Lewis E.J.","year":"2001","unstructured":"Lewis EJ, Hunsicker LG, Clarke WR. N Engl J Med, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes., 2001, 345, 851-860,","journal-title":"N Engl J Med"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","volume":"349","author":"","year":"1997","unstructured":". Lancet, Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy., 1997, 349, 1857-1863,","journal-title":"Lancet"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","volume":"288","author":"Wright J.T.","year":"2002","unstructured":"Wright JT, Bakris G, Greene T. JAMA, Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial., 2002, 288, 2421-2431,","journal-title":"JAMA"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"Yusuf S.","year":"2008","unstructured":"Yusuf S, Teo KK, Pogue J. N Engl J Med, Telmisartan, ramipril, or both in patients at high risk for vascular events., 2008, 358, 1547-1559,","journal-title":"N Engl J Med"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"Parving H.H.","year":"2012","unstructured":"Parving HH, Brenner BM, McMurray JJ. N Engl J Med, Cardiorenal end points in a trial of aliskiren for type 2 diabetes., 2012, 367, 2204-2213,","journal-title":"N Engl J Med"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","volume":"369","author":"Fried L.F.","year":"2013","unstructured":"Fried LF, Emanuele N, Zhang JH. N Engl J Med, Combined angiotensin inhibition for the treatment of diabetic nephropathy., 2013, 369, 1892-1903,","journal-title":"N Engl J Med"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"Whelton P.K.","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS. Hypertension, 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines., 2018, 71, 1269-1324,","journal-title":"Hypertension"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.2337\/dc18-S009","volume":"41","author":"","year":"2018","unstructured":". Diabetes Care, 9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2018., 2018, 41, S86-S104,","journal-title":"Diabetes Care"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","volume":"47","author":"Schjoedt K.J.","year":"2004","unstructured":"Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH. Diabetologia, Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate., 2004, 47, 1936-1939,","journal-title":"Diabetologia"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","volume":"1","author":"Chrysostomou A.","year":"2006","unstructured":"Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Clin J Am Soc Nephrol, Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker., 2006, 1, 256-262,","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","volume":"24","author":"van den Meiracker A.H.","year":"2006","unstructured":"van den Meiracker AH, Baggen RG, Pauli S. J Hypertens, Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function., 2006, 24, 2285-2292,","journal-title":"J Hypertens"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","volume":"28","author":"Rossing K.","year":"2005","unstructured":"Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Diabetes Care, Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study., 2005, 28, 2106-2112,","journal-title":"Diabetes Care"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","volume":"68","author":"Schjoedt K.J.","year":"2005","unstructured":"Schjoedt KJ, Rossing K, Juhl TR. Kidney Int, Beneficial impact of spironolactone in diabetic nephropathy., 2005, 68, 2829-2836,","journal-title":"Kidney Int"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","volume":"70","author":"Schjoedt K.J.","year":"2006","unstructured":"Schjoedt KJ, Rossing K, Juhl TR. Kidney Int, Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy., 2006, 70, 536-542,","journal-title":"Kidney Int"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","volume":"20","author":"Mehdi U.F.","year":"2009","unstructured":"Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. J Am Soc Nephrol, Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy., 2009, 20, 2641-2650,","journal-title":"J Am Soc Nephrol"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s10157-015-1106-2","volume":"19","author":"Kato S.","year":"2015","unstructured":"Kato S, Maruyama S, Makino H. Clin Exp Nephrol, Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial., 2015, 19, 1098-1106,","journal-title":"Clin Exp Nephrol"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2310\/JIM.0b013e31816d78e9","volume":"56","author":"Saklayen M.G.","year":"2008","unstructured":"Saklayen MG, Gyebi LK, Tasosa J, Yap J. J Investig Med, Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial., 2008, 56, 714-719,","journal-title":"J Investig Med"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","volume":"70","author":"Bianchi S.","year":"2006","unstructured":"Bianchi S, Bigazzi R, Campese VM. Kidney Int, Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease., 2006, 70, 2116-2123,","journal-title":"Kidney Int"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1053\/j.ajkd.2009.11.006","volume":"55","author":"Bianchi S.","year":"2010","unstructured":"Bianchi S, Bigazzi R, Campese VM. Am J Kidney Dis, Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases., 2010, 55, 671-681,","journal-title":"Am J Kidney Dis"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1291\/hypres.31.59","volume":"31","author":"Furumatsu Y.","year":"2008","unstructured":"Furumatsu Y, Nagasawa Y, Tomida K. Hypertens Res, Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker., 2008, 31, 59-67,","journal-title":"Hypertens Res"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3109\/08860220903150312","volume":"31","author":"Guney I.","year":"2009","unstructured":"Guney I, Selcuk NY, Altintepe L, Atalay H, Ba\u015farali MK, B\u00fcy\u00fckba\u015f S. Ren Fail, Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease., 2009, 31, 779-784,","journal-title":"Ren Fail"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","volume":"1","author":"Epstein M.","year":"2006","unstructured":"Epstein M, Williams GH, Weinberger M. Clin J Am Soc Nephrol, Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes., 2006, 1, 940-951,","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"e26904","DOI":"10.1371\/journal.pone.0026904","volume":"6","author":"Boesby L.","year":"2011","unstructured":"Boesby L, Elung-Jensen T, Klausen TW, Strandgaard S, Kamper AL. PLoS One, Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study., 2011, 6, e26904-,","journal-title":"PLoS One"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","volume":"2","author":"Ando K.","year":"2014","unstructured":"Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T. Lancet Diabetes Endocrinol, Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial., 2014, 2, 944-953,","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1159\/000343391","volume":"36","author":"Tylicki L.","year":"2012","unstructured":"Tylicki L, Lizakowski S, Rutkowski P. Kidney Blood Press Res, The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?, 2012, 36, 335-343,","journal-title":"Kidney Blood Press Res"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","volume":"7","author":"B\u00e4rfacker L.","year":"2012","unstructured":"B\u00e4rfacker L, Kuhl A, Hillisch A. ChemMedChem, Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases., 2012, 7, 1385-1403,","journal-title":"ChemMedChem"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/14656566.2017.1328054","volume":"18","author":"Sarafidis P.A.","year":"2017","unstructured":"Sarafidis PA, Alexandrou ME, Ruilope LM. Expert Opin Pharmacother, A review of chemical therapies for treating diabetic hypertension., 2017, 18, 909-923,","journal-title":"Expert Opin Pharmacother"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","volume":"31","author":"Katayama S.","year":"2017","unstructured":"Katayama S, Yamada D, Nakayama M. J Diabetes Complications, A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy., 2017, 31, 758-765,","journal-title":"J Diabetes Complications"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2215\/CJN.01150112","volume":"7","author":"Sarafidis P.A.","year":"2012","unstructured":"Sarafidis PA, Blacklock R, Wood E. Clin J Am Soc Nephrol, Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic., 2012, 7, 1234-1241,","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1517\/14740330903499257","volume":"9","author":"Sarafidis P.A.","year":"2010","unstructured":"Sarafidis PA, Georgianos PI, Lasaridis AN. Expert Opin Drug Saf, Diuretics in clinical practice. Part II: electrolyte and acid-base disorders complicating diuretic therapy., 2010, 9, 259-273,","journal-title":"Expert Opin Drug Saf"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1053\/j.ajkd.2010.01.020","volume":"56","author":"Palmer B.F.","year":"2010","unstructured":"Palmer BF. Am J Kidney Dis, A physiologic-based approach to the evaluation of a patient with hyperkalemia., 2010, 56, 387-393,","journal-title":"Am J Kidney Dis"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1532-5415.2011.03818.x","volume":"60","author":"Drawz P.E.","year":"2012","unstructured":"Drawz PE, Babineau DC, Rahman M. J Am Geriatr Soc, Metabolic complications in elderly adults with chronic kidney disease., 2012, 60, 310-315,","journal-title":"J Am Geriatr Soc"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.ejim.2009.07.002","volume":"20","author":"Drion I.","year":"2009","unstructured":"Drion I, Joosten H, Dikkeschei LD, Groenier KH, Bilo HJ. Eur J Intern Med, eGFR and creatinine clearance in relation to metabolic changes in an unselected patient population., 2009, 20, 722-727,","journal-title":"Eur J Intern Med"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/j.1523-1755.2000.00381.x","volume":"58","author":"Bakris G.L.","year":"2000","unstructured":"Bakris GL, Siomos M, Richardson D. Kidney Int, ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure., 2000, 58, 2084-2092,","journal-title":"Kidney Int"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","volume":"334","author":"Maschio G.","year":"1996","unstructured":"Maschio G, Alberti D, Janin G. N Engl J Med, Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency., 1996, 334, 939-945,","journal-title":"N Engl J Med"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1136\/bmj.309.6958.833","volume":"309","author":"Hannedouche T.","year":"1994","unstructured":"Hannedouche T, Landais P, Goldfarb B. BMJ, Randomised controlled trial of enalapril and \u03b2 blockers in non-diabetic chronic renal failure., 1994, 309, 833-837,","journal-title":"BMJ"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"Juurlink D.N.","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS. N Engl J Med, Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study., 2004, 351, 543-551,","journal-title":"N Engl J Med"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","volume":"78","author":"","year":"1996","unstructured":". Am J Cardiol, Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])., 1996, 78, 902-907,","journal-title":"Am J Cardiol"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","volume":"51","author":"Bomback A.S.","year":"2008","unstructured":"Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Am J Kidney Dis, Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review., 2008, 51, 199-211,","journal-title":"Am J Kidney Dis"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000237742","volume":"30","author":"Khosla N.","year":"2009","unstructured":"Khosla N, Kalaitzidis R, Bakris GL. Am J Nephrol, Predictors of hyperkalemia risk following hypertension control with aldosterone blockade., 2009, 30, 418-424,","journal-title":"Am J Nephrol"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1517\/14656566.2015.1083977","volume":"16","author":"Sarafidis P.A.","year":"2015","unstructured":"Sarafidis PA, Georgianos PI, Bakris GL. Expert Opin Pharmacother, Advances in treatment of hyperkalemia in chronic kidney disease., 2015, 16, 2205-2215,","journal-title":"Expert Opin Pharmacother"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","volume":"32","author":"Pitt B.","year":"2011","unstructured":"Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ. Eur Heart J, Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial., 2011, 32, 820-828,","journal-title":"Eur Heart J"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"Weir M.R.","year":"2015","unstructured":"Weir MR, Bakris GL, Bushinsky DA. N Engl J Med, Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors., 2015, 372, 211-221,","journal-title":"N Engl J Med"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","volume":"372","author":"Packham D.K.","year":"2015","unstructured":"Packham DK, Rasmussen HS, Lavin PT. N Engl J Med, Sodium zirconium cyclosilicate in hyperkalemia., 2015, 372, 222-231,","journal-title":"N Engl J Med"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/phar.1906","volume":"37","author":"Meaney C.J.","year":"2017","unstructured":"Meaney CJ, Beccari MV, Yang Y, Zhao J. Pharmacotherapy, Systematic Review and Meta-Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia., 2017, 37, 401-411,","journal-title":"Pharmacotherapy"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/170508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T17:43:09Z","timestamp":1558806189000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/170508\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,26]]},"references-count":71,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2019,4,26]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612825666190306162658","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,26]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}